How Is Vaginal Endometrial Stromal Sarcoma Treated?

Vaginal endometrial stromal sarcoma (ESS) is an exceedingly rare malignant tumor arising from the endometrial stromal cells within the vaginal wall—distinct from primary uterine ESS and representing a true vaginal primary neoplasm. Due to its rarity, no standardized treatment protocol exists; however, current clinical practice is guided by case reports, small series, and extrapolation from uterine ESS management principles.

Complete surgical excision remains the cornerstone of therapy. The goal is wide local resection with negative margins, often requiring partial or total vaginectomy depending on tumor size, location, and depth of infiltration. In cases involving adjacent structures—such as the bladder, rectum, or pelvic sidewall—multidisciplinary collaboration with urologic or colorectal surgeons may be necessary to achieve oncologic clearance. Lymphadenectomy is not routinely indicated, as lymph node metastasis is uncommon in vaginal ESS, though sentinel lymph node mapping may be considered in select high-risk cases.

Adjuvant therapy is individualized. Hormonal therapy—particularly with gonadotropin-releasing hormone (GnRH) agonists or aromatase inhibitors—is frequently employed given the tumor’s typical estrogen and progesterone receptor positivity. This approach may be used postoperatively for residual disease, recurrent disease, or in patients who are not surgical candidates. Radiation therapy has a limited but potentially valuable role, especially for margin-positive resections or unresectable localized disease, though evidence is sparse due to the paucity of cases.

Systemic chemotherapy is reserved for advanced, metastatic, or recurrent disease unresponsive to hormonal interventions. Regimens often mirror those used for uterine sarcomas—including doxorubicin-based combinations or gemcitabine/docetaxel—but response rates remain modest and data are largely anecdotal.

Long-term surveillance is essential, incorporating regular pelvic examination, imaging (e.g., MRI or contrast-enhanced CT), and consideration of serum tumor markers if clinically relevant. Given the indolent yet persistent nature of many ESS variants, recurrences may manifest years after initial treatment—necessitating lifelong follow-up.